2. 您的位置
3. 首页
4. 会议论文
5. Cisplatin and Fluorouracil Alone or with Docetaxel in Nasopharyngeal carcinoma:Interim Analysis of a

Cisplatin and Fluorouracil Alone or with Docetaxel in Nasopharyngeal carcinoma:Interim Analysis of a

来源 :第七届全国鼻咽癌学术大会 | 被引量 : 0次 | 上传用户：nengding

【摘 要】

：

Background:A randomized phase 3 trial of the treatment of nasopharyngeal carcinoma compared induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) with cisplatin and fluorouracil

【作 者】

：

Ting Jin Xiao-zhong Chen Fu-jun Hu Feng Jiang Wei-feng Qin Bin Li Xing-lai Feng Qi-feng Jing 

【机 构】

：

Department of Radiation Oncology,Zhejiang Cancer Hospital,Hangzhou,Zhejiang 310022,People's Republi

【出 处】

：

第七届全国鼻咽癌学术大会

【发表日期】

：

2015年9期

【关键词】

：

nasopharyngeal carcinoma docetaxel cisplatin fluorouracil induction chemotherapy 

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Background:A randomized phase 3 trial of the treatment of nasopharyngeal carcinoma compared induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) with cisplatin and fluorouracil (PF) ,followed by chemoradiotherapy.

其他文献

TPF方案诱导化疗加紫杉醇或顺铂同期放、化疗治疗局部晚期鼻咽癌的疗效分析

[目的]分析TPF方案诱导化疗加同期调强放疗(IMRT)治疗局部晚期鼻咽癌的疗效及预后分析.[方法]回顾我院2008年8月～2012年12月初治的局部晚期鼻咽癌患者263例,采用TPF方案(多西紫杉醇75mg/m2,d1,静滴；顺铂75mg/m2,d1～5,持续静脉泵滴入,10AM～ 10PM；5-氟尿嘧啶750mg/(m2·d),d1～d5,持续静脉泵滴入,10PM～ 10AM)诱导化疗2～3个

会议

鼻咽癌调强放射治疗同步放化疗诱导化疗

Evaluation of Induction Chemotherapy with Docetaxel plus Cisplatin and 5-Fu (TPF) or Docetaxel plus

Objective:To compare the efficacy and side effects of induction chemotherapy with docetaxel plus cisplatin and 5-Fu(TPF) or docetaxel plus cisplatin(TP) or gemcitabine plus cisplatin(GP) combined with

会议

Efficacy and Safety of Endostar Combined with Chemoradiotherapy for Patients with Advanced Locally R

Purpose:To evaluate the short-term efficacy and safety of recombinant human endostatin(Endostar) combined with chemoradiotherapy in the treatment of advanced locally recurrent nasopharyngeal carcinoma

会议

endostarnasopharyngeal carcinomarecurrencechemotherapyintensity-modulated ra

重组人血管内皮抑制素联合放化疗治疗局部晚期鼻咽癌的初步临床研究

[目的]观察重组人血管内皮抑制素联合诱导化疗序贯同步放化疗治疗局部晚期鼻咽癌的近期疗效、耐受性和安全性。[方法] 2011年12月30日至2013年3月31日,53例局部晚期鼻咽癌患者接受两周期TP方案诱导化疗联合重组人血管内皮抑制素,随后序贯重组人血管内皮抑制素联合DDP同步放化疗(试验组)；选取48例局部晚期鼻咽癌患者采用两周期TP方案诱导化疗,随后序贯序贯DDP(顺铂)同步放化疗(对照组)。

会议

静脉滴注重组人p53腺病毒注射液联合放化疗治疗晚期鼻咽癌的安全性和近期疗效评价

[背景]腺病毒介导的p53肿瘤基因治疗是一种有前景的抗肿瘤手段，通过恢复野生型p53功能，达到抑制肿瘤的目的。在过去的十多年里，大量临床研究表明瘤体内注射、腹膜内注射、膀胱内注射重组人p53腺病毒注射液均是安全有效的抗肿瘤手段。[目的]本研究针对rAd-p53静脉递药系统给药，对重组人p53腺病毒注射液(rAd-p53)联合放化疗治疗晚期鼻咽癌的安全性和近期疗效进行了回顾性研究。

会议

将顺铂纳米碳混悬液应用于鼻咽癌靶向化疗的研究

[目的]明确纳米炭—顺铂混悬液对鼻咽癌转移淋巴结有明显治疗效果，证明纳米炭—顺铂混悬液具有靶向化疗作用。[方法]将纳米炭吸附化疗药物顺铂后，注射于鼻咽癌患者鼻咽部病灶，通过纳米炭的靶向输送能力，使化疗药物输送并聚集于鼻咽癌转移的前哨淋巴结，达到定向化疗的目的。严格按照技术要求制备药物后，分两种检验方法进行试验。第一阶段进行纳米炭靶向运药能力研究，设立纳米炭—顺铂混悬液(DDP-CNP)组、顺铂(D

会议

纳米炭-顺铂混悬鼻咽癌颈淋巴结转移99mTc显影靶向化疗

A Phase Ⅱ Trial of Endostar Combined with Gemcitabine and Cisplatin Chemotherapy in Patients with Me

Despite the efficacy of gemcitabine-cisplatin (GC) regimens,the outcome of patients with metastatic nasopharyngeal carcinoma (MNPC) is poor.We conducted a phase Ⅱ trial to determine the safety and eff

会议

nasopharyngeal neoplasmsendostarcisplatingemcitabinemetastasis

Evaluation of the Efficacy and Safety of a Neoadjuvant Gemcitabine and Nedaplatin Regimen Followed b

Objective:To evaluate the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin chemotherapy regimen followed by concurrent chemoradiotherapy or radiotherapy alone in locoregionally advanced

会议

nasopharyngeal carcinomagemcitabinenedaplatininduction chemotherapychemoradi

Arterial Interventional Chemotherapy and IMRT with Concurrent Chemotherapy for Nasopharyngeal Carcin

The aim of this study was to ensure a high dose of intensity modulated radiation therapy(IMRT) was delivered to tumor tissue with a low dose to normal organs.Seldinger interventional techniques were u

会议

Comparison of Efficacy and Safety between Cisplatin and Nadaplatin Included Chemotherapy Regiments f

Backgroud: For the locogegionally advanced nasopharyngeal carcinoma (NPC) patients, radiotherapy plus chemotherapy has been the gold standard treatment reiment.However, the cisplatin based chemotherap

会议